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ABSTRACT A recent study conducted in blood has proposed CD32 as the marker
identifying the “elusive” HIV reservoir. We have investigated the distribution of
CD32 CD4 T cells in blood and lymph nodes (LNs) of HIV-1-uninfected subjects and
viremic untreated and long-term-treated HIV-1-infected individuals and their rela-
tionship with PD-1 CD4 T cells. The frequency of CD32 CD4 T cells was increased
in viremic compared to treated individuals in LNs, and a large proportion (up to
50%) of CD32 cells coexpressed PD-1 and were enriched within T follicular helper
(Tfh) cells. We next investigated the role of LN CD32 CD4 T cells in the HIV reser-
voir. Total HIV DNA was enriched in CD32 and PD-1 CD4 T cells compared to
CD32 and PD-1 cells in both viremic and treated individuals, but there was no
difference between CD32 and PD-1 cells. There was no enrichment of latently in-
fected cells with inducible HIV-1 in CD32 versus PD-1 cells in antiretroviral ther-
apy (ART)-treated individuals. HIV-1 transcription was then analyzed in LN memory
CD4 T cell populations sorted on the basis of CD32 and PD-1 expression. CD32
PD-1 CD4 T cells were signiﬁcantly enriched in cell-associated HIV RNA compared
to CD32 PD-1 (averages of 5.2-fold in treated individuals and 86.6-fold in vire-
mics), CD32 PD-1 (2.2-fold in treated individuals and 4.3-fold in viremics), and
CD32 PD-1 (2.2-fold in ART-treated individuals and 4.6-fold in viremics) cell popu-
lations. Similar levels of HIV-1 transcription were found in CD32 PD-1 and CD32
PD-1 CD4 T cells. Interestingly, the proportion of CD32 and PD-1 CD4 T cells
negatively correlated with CD4 T cell counts and length of therapy. Therefore, the
expression of CD32 identiﬁes, independently of PD-1, a CD4 T cell population with
persistent HIV-1 transcription and coexpression of CD32 and PD-1, the CD4 T cell
population with the highest levels of HIV-1 transcription in both viremic and treated
individuals.
IMPORTANCE The existence of long-lived latently infected resting memory CD4 T
cells represents a major obstacle to the eradication of HIV infection. Identifying cell
markers deﬁning latently infected cells containing replication-competent virus is im-
portant in order to determine the mechanisms of HIV persistence and to develop
novel therapeutic strategies to cure HIV infection. We provide evidence that PD-1
and CD32 may have a complementary role in better deﬁning CD4 T cell populations
infected with HIV-1. Furthermore, CD4 T cells coexpressing CD32 and PD-1 identify a
CD4 T cell population with high levels of persistent HIV-1 transcription.
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The existence of long-lived latently HIV-1-infected resting memory CD4 T cellsrepresents a major obstacle to the eradication of HIV infection (1–6). Several studies
in recent years have greatly contributed to the characterization of different CD4 T cell
populations containing inducible replication-competent HIV-1. In the blood, central
memory CD4 T cells deﬁned by the CD45RA CCR7 CD27 phenotype and transi-
tional memory CD4 T cells deﬁned by the CD45RA CCR7 CD27 phenotype have
been identiﬁed as major cellular compartments of the latent HIV-1 reservoir, while CD4
T cells with stem cell-like properties have been identiﬁed as a minor component (7, 8).
Recent studies performed in blood have also shown that a series of markers such as
PD-1, LAG-3, HLA-DR, CCR6, TIGIT, and CD30 help to deﬁne CD4 T cell populations
infected with HIV-1 (9–11). Studies performed in memory CD4 T cell populations
isolated from lymph nodes (LNs) of viremic and long-term-treated HIV-1-infected
individuals have demonstrated that PD-1-positive and T follicular helper (Tfh) CD4 T
cells are the major reservoir for replication-competent and infectious virus in both
viremic and long-term-treated individuals (12, 13). A recent study performed in blood
has proposed that the low-afﬁnity receptor for the immunoglobulin G Fc fragment,
CD32a, deﬁnes a small population of HIV-1-infected resting CD4 T cells and therefore
that CD32a CD4 T cells represent the elusive HIV reservoir (14). A recent study has
challenged the ﬁndings that CD32a is a marker deﬁning the elusive HIV reservoir (15).
CD32 CD4 T cells expressed several markers of activation, and they are not enriched
in HIV DNA, while they are enriched for transcriptionally active HIV in long-term-treated
individuals. Along the same line, another study performed in blood also failed to show
enrichment of HIV-infected CD4 T cells within CD32 cells (16). On the basis of the
CD32a study and our previous observations on the role of PD-1/Tfh cells in the HIV
reservoir (12–14), we have addressed the following issues: (i) the differences in the
percentages of CD32 CD4 T cells in HIV-uninfected versus HIV-infected individuals; (ii)
the distribution of CD32 in blood versus lymphoid tissue, i.e., LNs; (iii) the distribution
of CD32 in different populations of memory CD4 T cells; and (iv) the relationship
between CD32 and PD-1 CD4 T cell populations and their role in deﬁning the HIV
reservoir.
(This article was submitted to an online preprint archive [17].)
RESULTS
Distribution of CD32 CD4 T cells in blood and lymph nodes. Blood and LN
biopsy specimens were obtained from 9 HIV-uninfected subjects, 19 long-term anti-
retroviral therapy (ART)-treated individuals, and 9 viremic individuals (Table 1). In
HIV-uninfected individuals, lymph node biopsy specimens were obtained from patients
undergoing vascular surgery. A small percentage (1%) of memory CD4 T cells in blood
expressed CD32, but there were no signiﬁcant differences between HIV-uninfected,
long-term ART-treated, and viremic individuals (Fig. 1A and B). Memory CD4 T cells from
LNs of the same individuals contained signiﬁcantly higher percentages of CD32 cells
than in blood (P  0.003 for HIV-uninfected individuals, P  0.0001 for ART-treated
individuals, and P  0.003 for viremics). The percentage of LN CD32 CD4 T cells was
signiﬁcantly higher in viremics than in long-term ART-treated individuals (Fig. 1A and
B) (P  0.0007) but not HIV-uninfected individuals (Fig. 1A and B).
These results indicate that CD32 expression in memory CD4 T cells from blood and
LNs is not restricted to HIV-1-infected individuals and that CD32 CD4 T cells are greatly
enriched in LNs.
Distribution of CD32 in LN and blood memory CD4 T cell populations. Next, we
investigated the distribution of CD32 in different memory LN CD4 T cell populations
deﬁned by the expression of CXCR5 and PD-1 in HIV-uninfected, long-term ART-treated,
and viremic individuals. Memory CD32 CD4 T cells were consistently enriched in
PD-1 CXCR5 and PD-1 CXCR5 CD4 T cell populations in the three study groups
(P  0.05 for all study groups) (Fig. 2A and B). The PD-1 CXCR5 CD4 T cells
correspond to Tfh cells (12, 18–20). PD-1 CD4 T cells were greatly enriched within the
CD32 CD4 T cell population in the three study groups, and 40 and 50% of PD-1 CD4
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T cells coexpressed PD-1 and CD32 in long-term ART-treated and viremic individuals,
respectively (Fig. 2C) (P  0.0001 for HIV-uninfected and ART-treated individuals and
P  0.003 for viremics). Similarly, substantial proportions of Tfh cells, ranging between
10% in ART-treated individuals and 20% in viremic individuals, were contained within
the CD32 CD4 T cell population (Fig. 2D) (P  0.0001 and P  0.003, respectively).
However, compared to the CD32 CD4 T cell population, Tfh cells were signiﬁcantly
enriched within the PD-1 CD4 T cell population (P  0.0001) (Fig. 2E). The distribution
of memory CD4 T cell populations deﬁned by CD32 and PD-1 was also investigated in
blood (Fig. 3A and B). The CD32 PD-1 CD4 T cell population was signiﬁcantly
reduced in viremic individuals compared to HIV-uninfected subjects (P  0.002). No
differences in the percentages of CD32 PD-1 and CD32 PD-1 CD4 T cells were
observed in the three study groups, while percentages of CD32 PD-1 CD4 T cells
were signiﬁcantly increased in viremic individuals (13.1% in viremics versus 4.3% in
HIV-uninfected individuals [P  0.0005] and 6.1% in treated individuals [P  0.01]).
Relationship between CD32 and PD-1 CD4 T cell populations. The simulta-
neous assessment by mass cytometry of 30 phenotypic markers deﬁning different cell
lineages, memory differentiation, cell activation, and cell trafﬁcking has provided the
possibility to analyze the differences between CD32 and CD32 lymph node memory
CD4 T cell populations in the three study groups in more depth. The levels of the large
majority (13 out of 16) of markers deﬁning chemokine receptors (CXCR3, CCR6, and
CCR4), cell activation (CD25, CD38, and HLA-DR), memory cell differentiation (ICOS,
CD57, CD27, CD127, CXCR5, PD-1, and CD40L), and HIV-1 coreceptors (CCR5 and
CXCR4) were greatly increased in CD32 compared to CD32 CD4 T cells regardless of
the study group (Fig. 4A). Only CCR7, CD127, and CD27 were unchanged. The heat
maps in Fig. 4A also show the differences among the study groups. The levels of ICOS,
CD38, and PD-1 were enhanced within CD32 cells (P  0.0001), while the levels of
CCR4 and CD127 were slightly reduced within CD32 cells in viremic individuals.
TABLE 1 Study cohort: clinical data
Patient
Age
(yr) Sexa
Duration of HIV
infection (yr)
Yr of
suppressive
ART
Viral load
(copies/ml)
CD4 count
(cells/l) ART status
MP106 37 M 0.1 0 160,000 501 Treatment naive
MP140 23 M 0.08 0 360,000 427 Treatment naive
MP119 23 M 1.3 0 13,000 498 Treatment naive
MP124 46 F 0.06 0 510,000 468 Treatment naive
MP117 51 M 5.42 0 54,000 504 Treatment naive
MP125 35 M 0.16 0 17,000 511 Treatment naive
MP118 29 M 0.06 0 14,000 538 Treatment naive
SA150 53 M 10 0 6,900 578 Treatment naive
SA143 37 M 0.3 0 25,000 704 Treatment naive
MP129 44 M 14.85 14.71 20 928 ART treated
MP068-1 45 M 3.33 3 20 928 ART treated
MP136 44 M 7.5 6 20 732 ART treated
MP123 61 M 9.25 9 20 1,270 ART treated
MP137 39 M 3.59 2.84 24 700 ART treated
MP064 36 M 7.88 4.49 20 719 ART treated
MP141 31 M 11.56 1.5 20 558 ART treated
MP094 47 M 8 8 20 451 ART treated
MP058 46 F 10.86 10 20 666 ART treated
MP082 53 M 22.45 8 20 1,236 ART treated
MP096 54 F 18 13 20 1,253 ART treated
MP103 41 M 1.62 1.16 20 217 ART treated
MP068-2 47 M 5.12 5 20 487 ART treated
MP060 42 M 21 8 20 786 ART treated
MP067 41 M 14.01 14 20 609 ART treated
MP072 47 M 18 2 20 614 ART treated
MP070 55 M 7.06 2 20 615 ART treated
MP100 36 F 13.06 10 20 643 ART treated
MP145 39 M 8.35 4 20 820 ART treated
aM, male; F, female.
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Several markers were downregulated in ART-treated individuals compared even to
HIV-uninfected individuals.
Due to the overlap between CD32 and PD-1 CD4 T cell populations, the distri-
bution of the same panel of makers was analyzed in lymph node memory CD4 cell
subpopulations deﬁned by the expression of CD32 and PD-1 in the three study groups
(Fig. 4B). The heat maps and the Venn diagram show that the expression of PD-1
determines a clear separation between the four cell populations. It appears that PD-1
CD32 and PD-1 CD32 CD4 T cells on one side and PD-1 CD32 and PD-1 CD32
CD4 T cells on the other side share similar phenotypes and are closely related to each
other (Fig. 4B and C). The higher expression levels of markers such as CXCR5, ICOS,
CD57, CD40L, CD38, and HLA-DR and reduced expression levels of CD127 and CCR7
indicate that PD-1 CD4 T cell populations are at an advanced stage of differentiation
and activation. Of note, the expression of the HIV-1 coreceptors CCR5 and CXCR4 is
greatly enhanced in the PD-1 CD4 T cell populations (for CCR5 cells, 21.8% in CD32
PD-1 and 37% in CD32 PD-1 populations; for CXCR4 cells, 14.2% in CD32 PD-1
and 18% in CD32 PD-1 populations).
Taken together, these results indicate that there is great overlap between CD32
and PD-1 memory CD4 T cell populations in LNs of HIV-1-infected individuals.
Importantly, the expression of PD-1 independently of CD32 expression helps to deﬁne
CD4 T cells that are potentially more susceptible to HIV infection.
FIG 1 CD32 expression on CD4 T cells in LNs and blood of HIV-1-infected and uninfected individuals. LN
and PB mononuclear cells were isolated from the same HIV-uninfected (n  9), HIV-1-infected ART-
treated (n  19), and HIV-1-infected viremic (n  9) individuals. Cells were stained with anti-CD3,
anti-CD4, anti-CD45RA, and anti-CD32 antibodies. (A) Representative ﬂow cytometry proﬁles of blood
and LN memory (CD45RA) CD4 T cell populations expressing CD32 in representative HIV-1-uninfected,
ART-treated, and viremic subjects. (B) Cumulative data on the frequencies of CD32 memory CD4 T cells
in blood and LN mononuclear cells of HIV-1-uninfected, ART-treated, and viremic individuals. P values
were obtained by a Mann-Whitney test to compare the three groups and a Wilcoxon signed-rank test to
compare frequencies between blood and LNs. **, P  0.01; ***, P  0.001; ****, P  0.0001. Error bars
denote means  standard errors of the means (SEM).
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Role of PD-1 and CD32 memory CD4 T cell populations in the HIV reservoir.
Having deﬁned the distribution and the phenotypic relationship of PD-1 and CD32
memory CD4 T cell populations in blood and LNs, we sought to investigate the role of
these cell populations in the HIV reservoir through determining whether there is (i) an
enrichment of HIV DNA-containing cells in LN CD32 and PD-1 CD4 T cells, (ii) a
difference in the frequencies of HIV DNA-containing cells between LN CD32 and
PD-1 CD4 cells in viremic and long-term ART-treated individuals, (iii) a difference in
the frequencies of cells containing replication-competent HIV between LN CD32 and
PD-1 CD4 T cells in long-term-treated individuals, and (iv) a difference in HIV tran-
scription between LN CD32 and PD-1 CD4 T cells in long-term ART-treated individ-
uals. Memory CD4 T cells (CD45RA) isolated from lymph nodes of seven long-term
FIG 2 CD32 CD4 T cells from LNs are enriched in PD-1 and Tfh cells. (A) Representative ﬂow cytometry proﬁles
of CD32 expression in LN memory CD4 T cell populations deﬁned by PD-1 and CXCR5 expression in HIV-1-
uninfected and HIV-1-infected ART-treated and viremic individuals. (B) Cumulative data on the frequencies of
CD32 memory CD4 T cells within PD-1 CXCR5, PD-1 CXCR5, PD-1 CXCR5, and Tfh (PD-1 CXCR5) cell
populations isolated from LNs of 9 HIV-1-uninfected, 19 ART-treated, and 9 viremic individuals. (C) Percentages of
PD-1 cells in gated CD32 and CD32 memory (CD45RA) CD4 T cell populations in the three groups. (D)
Distribution of Tfh cells within CD32 and CD32memory CD4 T cell populations. (E) Distribution of Tfh cells within
CD32, CD32, and PD-1 CD4 T cell populations from lymph nodes. *, P  0.05; **, P  0.01; ****, P  0.0001
(values were obtained by a Wilcoxon signed-rank test, and error bars denote means  SEM).
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ART-treated and seven viremic individuals were sorted on the basis of CD32 and/or
PD-1 expression and analyzed for the presence of total HIV DNA. A caveat of this
analysis is that because of the overlap between CD32 and PD-1 CD4 T cell popula-
tions, a proportion of cells coexpressing PD-1 and CD32 is present in both sorted
CD32 and PD-1 cell populations (Fig. 5A). However, because of the limited number
of cells, particularly in LNs of ART-treated individuals, it was not possible to assess the
total HIV DNA in the four cell populations deﬁned by the expression of CD32 and PD-1
(CD32 PD-1, CD32 PD-1, CD32 PD-1, and CD32 PD-1). CD32 and PD-1
CD4 T cell populations were enriched in cells containing HIV DNA compared to CD32
and PD-1 cell populations. With regard to CD32 versus CD32 populations, the
differences were signiﬁcant in the ART-treated individuals (1.83-fold; P  0.01) and
viremics (23.7-fold; P  0.01) (Fig. 5B). With regard to PD-1 versus PD-1 CD4 T cell
populations, there was only a trend toward higher HIV DNA in PD-1 versus PD-1
populations in ART-treated individuals, while the differences were signiﬁcant in viremic
individuals (6.5-fold; P  0.01) (Fig. 5B).
These results show an enrichment of HIV-infected cells within CD32 and PD-1 LN
memory CD4 T cells but not a substantial difference between these cell populations.
The massive proportions of cells infected on the basis of the total HIV DNA content in
CD32 and PD-1 CD4 T cells are consistent with the phenotypic data (Fig. 4) showing
increased expression of HIV-1 coreceptors in these cell populations and indicate that
they may serve as a major reservoir of HIV-1.
To estimate the frequencies of HIV-1-infected cells containing inducible replication-
competent virus, a quantitative virus outgrowth assay (QVOA) was performed on three
FIG 3 Frequencies of blood memory CD4 T cell populations on the basis of CD32 and PD-1. (A)
Representative ﬂow cytometry proﬁles of blood memory (CD45RA) CD4 T cell populations expressing
CD32 and/or PD-1 from representative HIV-1-uninfected, ART-treated, and viremic individuals. (B) Cu-
mulative data on the frequencies of CD32 PD-1, CD32 PD-1, CD32 PD-1, and CD32 PD-1 CD4
T cell populations in blood mononuclear cells from HIV-1-uninfected (n  9) and HIV-1-infected
ART-treated (n  19) and viremic (n  9) individuals. **, P  0.01; ***, P  0.001 (values were obtained
by a Mann-Whitney test, and error bars denote means  SEM).
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ART-treated individuals. The objective of the QVOA was to determine whether the
exclusion of CD32 or PD-1 cells had a different impact on the frequency of HIV-1-
infected cells with inducible virus. Because of the limited number of cells isolated from
ART-treated individuals, it was not possible to perform the QVOA on CD32 and PD-1
CD4 T cell populations. For the QVOA, different cell concentrations (5-fold limiting
FIG 4 Mass cytometry analysis of LN memory CD4 T cells deﬁned by CD32 and/or PD-1 expression. Mass cytometry
staining was performed on LN mononuclear cells isolated from 9 HIV-1-uninfected, 16 HIV-1-infected ART-treated,
and 9 viremic individuals. Cells were stained with a panel of 30 cell surface markers (Table 2). (A and B) Heat maps
of mean marker expression levels in memory CD4 T cells deﬁned on the basis of CD32 (A) and CD32 and PD-1 (B)
expression. Columns (i.e., markers) are scaled to facilitate comparisons of expression values color-coded from blue
(low) to yellow (high). (C) Venn diagram summarizing common trends and the direction of changes for signiﬁcant
markers (as in panel B) in CD45RA CD4 T cells deﬁned on the basis of PD-1 and CD32 expression. Black arrows
indicate trends that are common to all study groups (HIV-uninfected, ART-treated, and viremic individuals). Green,
red, and blue arrows indicate trends that are speciﬁc to each study group.
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dilutions of 105, 2  104, and 4  103) and multiple replicates of sorted viable lymph
node CD32, PD-1, and total memory (CD45RA) CD4 T cells (Fig. 5A) were cocultured
with allogeneic fresh CD8 T cell-depleted blood mononuclear cells from HIV-1-
uninfected individuals, and frequencies were estimated at day 14 using an extreme
limiting-dilution assay (13, 21, 22). These analyses provide the average RNA units per
million (RUPM) for each cell population investigated. The frequencies of cells with
inducible HIV RNA in CD32 and PD-1 CD4 cell populations were not signiﬁcantly
different (Fig. 5C). In order to interpret these results correctly, it is important to consider
that by sorting out CD32 cells, there are still PD-1 cells remaining in the sorted
CD32 cell population (Fig. 5A). Since PD-1 cells also contain inducible HIV, it is
expected that there is a trend toward a reduction of the frequency of cells with
FIG 5 Levels of total HIV DNA and cell-associated HIV RNA in CD32 and PD-1 CD4 T cell populations. (A) Gating
strategy for CD32 and CD32 and PD-1 and PD-1memory (CD45RA) CD4 T cell populations. (B) Quantiﬁcation
of total HIV DNA (copies per million cells) of sorted memory (CD45RA) CD4 T cells expressing or not expressing
CD32 and PD-1 from 7 aviremic ART-treated (round circles) and 7 viremic (squares) individuals. (C) Frequencies of
cells with inducible replication-competent HIV in sorted CD32, PD-1, and total memory CD4 T cells estimated
using conventional limiting-dilution methods by extreme limiting-dilution analysis (http://bioinf.wehi.edu.au/
software/elda/) in 3 aviremic ART-treated individuals. (D) Gating strategy for CD32 PD-1, CD32 PD-1, CD32
PD-1, and CD32 PD-1 memory (CD45RA) CD4 T cell populations. (E) Levels of cell-associated unspliced HIV
RNA (copies/million cells) in sorted CD32 PD-1, CD32 PD-1, CD32 PD-1, and CD32 PD-1 memory CD4 T
cell populations isolated from 10 aviremic ART-treated and 6 viremic individuals. *, P  0.05; **, P  0.01; ns, not
signiﬁcant (values were obtained by a Wilcoxon signed-rank test, and error bars denote means  SEM).
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inducible HIV and not a more dramatic reduction. Along the same line, by sorting out
PD-1 cells, there are still CD32 cells remaining in the sorted PD-1 cell population,
which explains the partial reduction found. Finally, there was a trend toward higher
frequencies of cells with inducible HIV RNA in the total memory CD4 T cell population
than in the CD32 and PD-1 populations (Fig. 5C).
We have recently shown that PD-1 CD4 T cells serve as the major CD4 T cell
compartment in blood and LNs for replication-competent and infectious HIV-1 and for
active and persistent virus transcription in long-term ART-treated aviremic individuals
(13). We then investigated whether there was a difference in HIV transcription between
LN CD32 and PD-1 CD4 T cells in 10 long-term ART-treated and 6 viremic individuals.
To determine the cell compartment(s) serving as the site of active and persistent HIV-1
transcription, cell-associated HIV-1 RNA was assessed in LN memory CD32 PD-1,
CD32 PD-1, CD32 PD-1, and CD32 PD-1 CD4 T cell populations. The gating
strategy for cell sorting is shown in Fig. 5D. The results indicate that the levels of
cell-associated HIV-1 RNA were signiﬁcantly higher in CD32 PD-1 CD4 T cells than in
the other three cell populations (Fig. 5E). CD32 PD-1 CD4 T cells were enriched in
cell-associated HIV-1 RNA compared to CD32 PD-1 (averages of 5.2-fold in ART-
treated individuals and 86.6-fold in viremics), CD32 PD-1 (2.2-fold in ART-treated
individuals and 4.3-fold in viremics), and CD32 PD-1 (averages of 2.2-fold in ART-
treated individuals and 4.6-fold in viremics) cell populations. CD32 PD-1 and CD32
PD-1 cell populations also had signiﬁcantly higher levels of cell-associated HIV RNA
than CD32 PD-1 cells (P  0.05), while no differences were found between CD32
PD-1 and CD32 PD-1 cell populations.
Therefore, the coexpression of CD32 and PD-1 identiﬁes a population with greater
HIV transcriptional activity within Tfh cells, and the sole expression of CD32 identiﬁes
a cell population with levels of transcriptional activity similar to those measured in
single PD-1 CD4 T cells.
Recent results (23) have suggested that the expression of CD32 on blood CD4 T
cells was reﬂective of either the presence of doublets or partial exchange of B cell and
CD4 T cell membranes. We have also carefully addressed this issue in our ﬂow
cytometry experiments. The exclusion of doublets is a mandatory step in the ﬂow
cytometry analysis of cell populations. In the present study, we have totally excluded
that the expression of CD32 on lymph node CD4 T cells was the result of B-T cell
doublets. In the presence of B-CD4 T cell doublets, we should ﬁnd that the expression
of CD32 in the different memory CD4 T cell populations would also be associated with
the expression of CD19. The doublets have been excluded in two sequential analyses.
Similarly, CD19 B cells and CD8 T cells have been excluded when gating for CD4
T cells, and we have no evidence of CD19 expression on single CD32 CD4 T cells as
well as CD32 PD-1 CD4 T cells.
CD32 and PD-1 CD4 T cells and markers of HIV disease activity. We then
determined the relationship between CD32 and PD-1 CD4 T cells and indicators of
HIV disease activity and the length of suppressive ART. The percentage of CD32 and
PD-1 CD4 T cells negatively correlated with the CD4 T cell count (r  0.59 and P 
0.0008 and r  0.49 and P  0.007, respectively) (Fig. 6) and length of ART treatment
(r  0.66 and P  0.001 and r  0.49 and P  0.03, respectively) (Fig. 7A). Next, we
analyzed the relationships between the length of treatment and the percentages of the
four LN memory CD4 T cell populations gated on the basis of the expression of CD32
and PD-1. Interestingly, the percentage of CD32 PD-1 cells positively correlated with
the length of ART (r  0.49 and P  0.03), while the percentages of CD32 PD-1,
CD32 PD-1, and CD32 PD-1 cells negatively correlated with the length of ART
treatment (r  0.47 and P  0.03, r  0.48 and P  0.03, and r  0.76 and P 
0.0001, respectively) (Fig. 7B).
These results indicate that the expansion of both CD32 and PD-1 memory CD4 T
cell populations in lymph nodes correlates with markers of HIV disease activity.
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DISCUSSION
The percentage (range of 0.2 to 0.5%) of CD32 CD4 T cells and their intensity of
expression are extremely low in blood, thus rendering in-depth characterization of
circulating CD32 CD4 T cells challenging. For these reasons, we decided to study
FIG 6 Correlations between memory CD4 T cell populations deﬁned by CD32 and PD-1 CD4 counts.
Shown are correlations between the percentages of CD32 and PD-1 memory CD4 T cells and CD4 T
cell counts. A Spearman rank test was used for correlations.
FIG 7 Correlation between memory CD4 T cell populations deﬁned by CD32 and/or PD-1 and years of
suppressive ART. (A) Correlation between the percentages of CD32 and PD-1 memory CD4 T cells and
years of suppressive ART. (B) Correlation between the percentages of CD32 PD-1, CD32 PD-1, CD32
PD-1, and CD32 PD-1 populations and years of suppressive ART. A Spearman rank test was used for
correlations.
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CD32 CD4 T cells in LNs. Lymphoid tissues are the major anatomic compartment for
HIV replication, spreading, and persistence, and therefore, they are the ideal anatomic
compartment to understand the role of CD32 CD4 T cells in the HIV reservoir and their
relationship with PD-1/Tfh cells that have been shown to serve as a major reservoir for
HIV (13, 24–31). We have previously demonstrated that PD-1/Tfh cell populations
serve as a major reservoir for HIV-1 in both viremic and long-term ART-treated subjects
(12, 13). These observations are instrumental since they indicate that the expression of
PD-1 is a marker to deﬁne the dominant CD4 T cell population infected with HIV-1 and
containing replication-competent virus. Along the same line, both viremic and long-
term-treated subjects have been studied to better understand the role of CD32 in
deﬁning cell populations serving as a reservoir for HIV-1. The use of both groups of
patients is critical to provide insights into the kinetics of the HIV reservoir following
initiation of therapy and the changes occurring in the cell populations deﬁned by the
expression of PD-1 and CD32.
The percentages of CD32 CD4 T cells in the blood were similar in HIV-uninfected,
viremic, and ART-treated individuals. Higher percentages of CD32 CD4 T cells were
found in LNs in the three study groups and were signiﬁcantly expanded in viremic
individuals, but similar percentages were found in LNs of HIV-uninfected and treated
individuals, thus indicating that CD32 expression on CD4 T cells is not exclusive of HIV
infection, as proposed by Descours et al. (14).
CD32 and PD-1 CD4 T cell populations are tightly correlated, as indicated by the
large proportion (up to 50%) of CD32 CD4 T cells coexpressing PD-1. The coexpression
of PD-1 is important for understanding the status of activation and differentiation of
CD32 cells and their role in the HIV reservoir. Indeed, the expression of PD-1 together
with HLA-DR and CD38 in CD32 PD-1 and CD32 PD-1 CD4 T cells indicates that
these cell populations are associated with high levels of cell activation and advanced
differentiation compared to the CD32 PD-1 and CD32 PD-1 cell populations.
However, the CD32 PD-1 cell population deﬁnes a population of cells expressing
higher levels of CD25, CCR6, and CCR4. In addition, there are also increased expression
levels of CD127 and CCR7. Differently from PD-1 cells, this population expresses lower
levels of CD57, CXCR5, ICOS, CXCR3, and CCR5. Therefore, CD32 PD1 cells represent
a distinct population different from PD-1 cells and, at least in part, the double-
negative cell population (CD32 PD-1).
Of note, CD32 and PD-1 CD4 T cells expressed higher levels of the HIV-1
coreceptors CCR5 and CXCR4, thus rendering these cells a preferential target for HIV
infection. These data are consistent with two recent studies (15, 16) showing that
CD32 CD4 T cells express higher levels of activation markers and HIV coreceptors.
On the basis of the quantiﬁcation of the total HIV DNA and of cells with inducible
replication-competent HIV, CD32 and PD-1 CD4 T cells contribute equally to the HIV
reservoir in long-term-treated individuals, and there were also no differences found in
viremic individuals. More importantly, the analysis of cell-associated HIV RNA has
demonstrated equal levels of persistent HIV transcription in CD32 PD-1 and CD32
PD-1 CD4 T cell populations and signiﬁcantly higher levels of transcription in the
CD32 PD-1 cells. These ﬁndings are overall in agreement with data from a recent
study (15) that failed to conﬁrm the conclusions of Descours et al. that CD32 deﬁnes the
latent “elusive” HIV reservoir. However, the present study provides detailed information
on the phenotypic differences between CD32 PD-1 and CD32 PD-1 lymph node
CD4 T cell populations and a better delineation of the role of these distinct CD32 cell
populations in the HIV reservoir. The present results demonstrate that CD32 CD4 T
cells have high levels of HIV transcription. This ﬁnding is consistent with the observa-
tion that a large proportion of CD32 CD4 T cells is activated. As mentioned above, it
is important to underscore that about 50% of the CD32 CD4 T cell population that
coexpresses PD-1 and CD32 PD-1 lymph node CD4 T cells correspond to Tfh cells,
which have been previously shown to serve as the major CD4 T cell HIV reservoir in
both viremic and long-term ART-treated subjects (12, 13). However, CD32, indepen-
dently of PD-1, deﬁnes an additional population of memory CD4 T cells with persistent
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HIV transcription. When coexpressed with PD-1, CD32 deﬁnes the CD4 T cell population
with the highest levels of transcription.
In conclusion, the combined use of CD32 and PD-1 identify three cell populations,
CD32 PD-1, CD32 PD-1, and CD32 PD-1, of memory CD4 T cells responsible for
most of the persistent HIV transcription in long-term-treated individuals.
MATERIALS AND METHODS
Study groups. Samples from 9 HIV-uninfected subjects, 19 subjects on suppressive ART, and 9
viremic individuals not receiving ART at the time of sampling were used in this study. None of the
participants under ART had detectable plasma viremia at the time of the study, as assessed by viral load
measurements using AmpliPrep/Cobas TaqMan HIV-1 test v 2.0 (Roche), with a detection limit of 20 HIV
RNA copies/ml of plasma. All participants underwent lymph node biopsy (inguinal lymph nodes), and
blood was collected at the same time. Subject characteristics are summarized in Table 1. These studies
were approved by the Institutional Review Board of the Centre Hospitalier Universitaire Vaudois, and all
subjects gave written informed consent.
Cell isolation. Inguinal lymph node biopsy specimens and blood samples were collected on the
same day. Blood mononuclear cells were isolated as previously described (32), and lymph node
mononuclear cells were isolated by mechanical disruption (24). Blood mononuclear cells and lymph node
mononuclear cells were cryopreserved in liquid nitrogen.
Antibodies. The following antibodies were used: allophycocyanin (APC)-H7-conjugated anti-CD3
(clone SK7; BD), Paciﬁc Blue (PB)-conjugated anti-CD19 (clone HIB19; BioLegend), PB-conjugated CD8
(clone RPA-T8; BD) ﬂuorescein isothiocyanate (FITC)-conjugated anti-CXCR5 (clone RF8B2; BD), phyco-
erythrin (PE)-Cy7-conjugated anti-PD-1 (clone EH12.1; BD), Alexa 700 anti-CD4 (clone RPA-T4; BioLegend),
APC-conjugated anti-CD32 (FUN-2; BioLegend), and phycoerythrin-Texas Red (ECD)-conjugated anti-
CD45RA (clone 2H4; Beckman Coulter). An Aqua Live/Dead stain kit was used to determine the viability
of cells. Cells were acquired on an LSRII ﬂow cytometer using FACSDiva software (BD) and analyzed using
FlowJo 9.7 (TreeStar Inc.) or sorted using FACSAria (BD). The CD32 antibody used in the present study is
the same one used in the study by Descours et al., and this antibody does not discriminate between
CD32a and CD32b. We used a ﬂuorescence minus one (FMO) control to gate on CD32 cells.
CyTOF marker labeling and detection. Cryopreserved lymph node mononuclear cells were thawed
and resuspended in complete RPMI medium (Gibco, Life Technologies) (10% heat-inactivated fetal
TABLE 2Mass cytometry panel
Target Metal Company Clone
CD4 115In BioLegend RPA-T4
CCR6 141Pr Fluidigm/DVS G034E3
CD19 142Nd Fluidigm/DVS HIB19
ICOS 143Nd BioLegend C398.4A
CD8 145Nd BioLegend RPA-T8
IgD 146Nd Fluidigm/DVS IA6-2
CD7 147Sm Fluidigm/DVS CD7-6B7
CD57 148Nd BD G10F5
CCR4 149Sm Fluidigm/DVS 205410
CXCR5 153Eu Fluidigm/DVS RF8B2
CD21 152Sm Fluidigm/DVS BL13
CXCR3 154Sm BioLegend G025H7
CD27 155Gd Fluidigm/DVS L128
CD11c 156Gd BioLegend 3.9
CCR7 159Tb Fluidigm/DVS G043H7
CD25 158Gd BioLegend M-A251
CD14 160Gd Fluidigm/DVS M5E2
CD1C 161Dy BioLegend L161
CD32-APC 162Dy Fluidigm/DVS FUN2
CD20 166Er BioLegend 2H7
CD38 167Er Fluidigm/DVS HIT2
CD45RA 169Tm Fluidigm/DVS HI100
CD40L 168Er Fluidigm/DVS CD40L
CD3 170Er Fluidigm/DVS UCHT1
CCR5 171Yb Fluidigm/DVS NP-6G4
HLA-DR 173Yb Fluidigm/DVS L243
PD-1 174Yb Fluidigm/DVS EH12.2H7
CXCR4 175Lu Fluidigm/DVS 12G5
CD127 176Yb Fluidigm/DVS A019D5
CD16 209Bl Fluidigm/DVS 3G8
Live/Dead 195Pt Fluidigm/DVS Cell-ID
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bovine serum [FBS] [Institut de Biotechnologies Jacques Boy], 100 IU/ml penicillin, and 100 g/ml
streptomycin [BioConcept]) at 1  106 cells/ml.
Viability of cells in 500 l of phosphate-buffered saline (PBS) was assessed by incubation with 50 M
cisplatin (Sigma-Aldrich) for 5 min at room temperature (RT), and then the reaction was quenched with
500 l of fetal bovine serum. Next, cells were incubated for 20 min at 4°C with anti-CD32 APC antibody.
Next, cells were washed and incubated for 30 min at RT with a 50-l cocktail of cell surface metal-
conjugated antibodies (Table 2). Cells were washed and ﬁxed for 10 min at RT with 2.4% paraformal-
dehyde (PFA). Total cells were identiﬁed by DNA intercalation (1 M Cell-ID intercalator; Fluidigm/DVS
Science) in 2% PFA at 4°C overnight. Labeled samples were assessed by using a CyTOF1 instrument that
was upgraded to CyTOF2 (Fluidigm), using a ﬂow rate of 0.045 ml/min. Flow cytometry standard (FCS)
ﬁles were normalized to EQ Four Element calibration beads using CyTOF software. For conventional
cytometric analysis of memory CD4 T cell populations, FCS ﬁles were imported into Cytobank data
analysis software.
Quantiﬁcation of total HIV DNA. CD32, CD32, PD-1, and PD-1 memory (CD45RA) CD4 T cell
populations were sorted using a FACSAria instrument, and lysates were directly used in a nested PCR to
quantify both total HIV DNA and CD3 gene copy numbers, as previously described (7).
Quantiﬁcation of cell-associated RNA. Cell-associated HIV-1 RNA (unspliced HIV RNA encoding the
region between the 5’ long terminal repeats [5=-LTRs] and gag) from individual samples was quantiﬁed
from CD4 T cell populations sorted on the basis of CD32 and PD-1 expression (CD32 PD-1, CD32
PD-1, CD32 PD-1, and CD32 PD-1) and subjected to DNase treatment (RNAqueous-4PCR kit;
Ambion) (33). RNA standard curves were generated after isolation and quantiﬁcation of viral RNA from
the supernatant of an ACH2 culture as previously described (33). One-step cDNA synthesis and pream-
pliﬁcation were performed as previously described (34).
Quantitative viral outgrowth assay. Different cell concentrations (5-fold limiting dilutions of 105,
2  104, and 4  103 for lymph node CD4 T cells) and ﬁve replicates of sorted viable LN total memory
(CD45RA) and CD32 and PD-1 memory CD4 T cells isolated from three ART-treated HIV-1-infected
individuals were cultured with allogeneic fresh CD8-depleted blood mononuclear cells (106 cells/ml)
from HIV-1-uninfected subjects in the presence of anti-CD3/anti-CD28 monoclonal antibody (MAb)-
coated plates (10 g/ml) for 3 days (13, 22). Cells were carefully transferred to new uncoated plates after
3 days of activation. Cells under all conditions were cultured in complete RPMI for 14 days. Medium was
replaced at day 5. Supernatants were collected at day 14. The presence of HIV-1 RNA was assessed by
a Cobas AmpliPrep/TaqMan HIV-1 test (Roche, Switzerland). Wells with detectable HIV-1 RNA (20 HIV-1
RNA copies/ml) were referred to as HIV-1 RNA-positive wells. RUPM frequencies were estimated by
conventional limiting-dilution methods using extreme limiting-dilution analysis (http://bioinf.wehi.edu
.au/software/elda/) (21).
Statistical analysis. We performed a two-tailed Mann-Whitney test to compare frequencies of
CD32 CD4 T cells among HIV-1-uninfected and HIV-1-infected ART-treated and viremic individuals. A
Wilcoxon signed-rank test was used to compare different subsets. Correlative analyses were done using
a Spearman test. These analyses were done using Prism 7.0.
Statistical analyses comparing cell surface marker expression levels (nontransformed) (Fig. 4A and B)
in CD32 CD4 T cells and subsets deﬁned by CD32 and PD-1 (i.e., CD32 versus PD-1 quadrants) were
assessed using linear mixed-effect models on the frequencies of positive cells for each marker accounting
for differences between patient groups (HIV-1-uninfected, HIV-1-infected ART-treated, and viremic
individuals) with patient-level random intercepts. P values were adjusted using Bonferroni correction,
and data analysis was performed using R statistical software and the lmer package.
Data availability. All relevant data are within the paper.
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